Join the Opiate Dependence group to help and get support from people like you.
Opiate Dependence News (Page 7)
Related terms: Opioid Dependence, Opioid Use Disorder
Trends in Prehospital Encounters for Youth Opioid Overdose Identified
WEDNESDAY, Sept. 18, 2024 – Prehospital encounters for youth opioid overdoses increased before the COVID-19 pandemic, then increased with onset, and then stabilized, according to a research letter...
2020 to 2021 Saw Age-Adjusted Rates of Drug Overdose Rise in Colombia
TUESDAY, Sept. 17, 2024 – During 2010 to 2021, there was an increase in age-adjusted rates of drug overdoses in Colombia, especially from 2018 to 2021, according to a study published online Sept. 12...
Rx Up for Stimulants and Antidepressants, Down for Opioids, 2019 to 2022
MONDAY, Sept. 16, 2024 – Overall prescription volumes for stimulant and antidepressant medications increased from 2019 to 2022, while prescription volume for opioids decreased, according to a study...
FDA Approves Brixadi (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
Plymouth Meeting, Pa. – May 23, 2023—Braeburn announces that the U.S. Food and Drug Administration (FDA) has approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (CIII), a...
FDA Medwatch Alert: Opioid Pain Relievers or Medicines to Treat Opioid Use Disorder - FDA Recommends Health Care Professionals Discuss Naloxone with All Patients when Prescribing
ISSUE: FDA is requiring drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder (OUD) to add new recommendations about naloxone to the prescribing information....
FDA Approves Cassipa (buprenorphine and naloxone) Sublingual Film as Maintenance Treatment for Opioid Dependence
September 7, 2018 – The U.S. Food and Drug Administration today approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid...
FDA Approves Sublocade (buprenorphine) Once-Monthly Injection for Opioid Use Disorder
November 30, 2017 – The U.S. Food and Drug Administration today approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use...
FDA Medwatch Alert: Opioid Addiction Medications in Patients Taking Benzodiazepines or CNS Depressants: Drug Safety Communication - Careful Medication Management Can Reduce Risks
ISSUE: Based on additional review, FDA is advising that the opioid addiction medications buprenorphine and methadone should not be withheld from patients taking benzodiazepines or other drugs that...
FDA Approves Unique Low Dosage of Zubsolv
Uppsala, Sweden – October 6, 2016 – Orexo AB (publ.) announced today that it has received approval from the US Food and Drug Administration (FDA) of a new unique low dose, 0.7mg/0.18 mg, tablet of Zub...
FDA Approves Probuphine (buprenorphine) Implant for Treatment of Opioid Dependence
May 26, 2016 – The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide...
FDA Approves Zubsolv for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence
Uppsala, Sweden – August 11, 2015 - Orexo AB (publ) announced today that the U.S. Food and Drug Administration (FDA) has approved Zubsolv (buprenorphine/naloxone CIII sublingual tablet) for induction ...
FDA Approves Two Higher Dosage Strengths of Zubsolv
Uppsala, Sweden – December 12, 2014 – Orexo AB announces today that it has received approval from the U.S. Food and Drug Administration (FDA) of two higher dosage strengths of Zubsolv (bu...
FDA Approves Zubsolv for the Maintenance Treatment of Opioid Dependence
Uppsala, Sweden – July 4, 2013 – Orexo today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Zubsolv (buprenorphine/naloxone) sublingual tablet CIII. Zub...
FDA Approves Vivitrol to Treat Opioid-dependent Patients
ROCKVILLE, Md., Oct. 12, 2010--The U.S. Food and Drug Administration today approved Vivitrol to treat and prevent relapse after patients with opioid dependence have undergone detoxification...
Reckitt Benckiser Pharmaceuticals Inc. Receives FDA Approval for Suboxone (buprenorphine and naloxone) Sublingual Film C-III
Richmond, VA (31st August 2010) – Reckitt Benckiser Pharmaceuticals Inc. today announces that it has received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (...
Further information
Related condition support groups
Opiate Withdrawal, Opiate Dependence - Maintenance, Drug Dependence
Related drug support groups
Suboxone, naltrexone, Subutex, buprenorphine, Vivitrol, Sublocade, buprenorphine / naloxone